Lifang Yin

7.0k total citations · 1 hit paper
120 papers, 4.6k citations indexed

About

Lifang Yin is a scholar working on Molecular Biology, Biomaterials and Pharmaceutical Science. According to data from OpenAlex, Lifang Yin has authored 120 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Molecular Biology, 49 papers in Biomaterials and 29 papers in Pharmaceutical Science. Recurrent topics in Lifang Yin's work include Nanoparticle-Based Drug Delivery (48 papers), RNA Interference and Gene Delivery (25 papers) and Nanoplatforms for cancer theranostics (25 papers). Lifang Yin is often cited by papers focused on Nanoparticle-Based Drug Delivery (48 papers), RNA Interference and Gene Delivery (25 papers) and Nanoplatforms for cancer theranostics (25 papers). Lifang Yin collaborates with scholars based in China, United States and United Kingdom. Lifang Yin's co-authors include Wei He, Yaqi Lv, Imran Shair Mohammad, Lifang Fan, Jianping Zhou, Yiao Wang, Chao Qin, Ke Yang, Wei He and Shumin Zhu and has published in prestigious journals such as ACS Nano, Biomaterials and Scientific Reports.

In The Last Decade

Lifang Yin

110 papers receiving 4.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

International Journal of Pharmaceutics

2015 986 citations Yaqi Lv, Lifang Yin et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lifang Yin China	38	1.6k	1.6k	1.2k	1.1k	567	120	4.6k
Hyun‐Jong Cho South Korea	45	2.3k 1.4×	1.7k 1.1×	1.2k 1.0×	1.8k 1.8×	511 0.9×	224	6.3k
Vivek Gupta United States	38	1.3k 0.9×	1.6k 1.0×	1.1k 0.9×	1.2k 1.2×	362 0.6×	109	4.9k
Nagavendra Kommineni India	26	1.4k 0.9×	1.7k 1.1×	936 0.8×	1.0k 1.0×	295 0.5×	53	4.1k
Tuan Hiep Tran South Korea	34	1.2k 0.8×	1.2k 0.8×	864 0.7×	1.1k 1.0×	371 0.7×	91	3.4k
Meirong Huo China	30	1.9k 1.2×	1.6k 1.0×	1.6k 1.4×	1.4k 1.3×	604 1.1×	58	5.8k
Thiruganesh Ramasamy South Korea	38	1.7k 1.1×	1.4k 0.9×	871 0.7×	1.2k 1.1×	386 0.7×	60	3.6k
Donato Cosco Italy	43	1.8k 1.2×	1.8k 1.1×	1.3k 1.1×	1.2k 1.1×	346 0.6×	115	5.1k
Christian Celia Italy	47	1.8k 1.1×	2.2k 1.4×	1.6k 1.3×	1.2k 1.1×	334 0.6×	119	5.6k
Yong Gan China	46	2.1k 1.3×	2.4k 1.5×	2.3k 1.9×	1.5k 1.4×	433 0.8×	132	6.1k
Jingxin Gou China	34	1.1k 0.7×	983 0.6×	1.1k 1.0×	810 0.8×	300 0.5×	177	3.5k

Countries citing papers authored by Lifang Yin

Since Specialization

Citations

This map shows the geographic impact of Lifang Yin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lifang Yin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lifang Yin more than expected).

Fields of papers citing papers by Lifang Yin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lifang Yin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lifang Yin. The network helps show where Lifang Yin may publish in the future.

Co-authorship network of co-authors of Lifang Yin

This figure shows the co-authorship network connecting the top 25 collaborators of Lifang Yin. A scholar is included among the top collaborators of Lifang Yin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lifang Yin. Lifang Yin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Xia, Yanming, Yanming Xia, Linghui Peng, et al.. (2025). Trapping effect of surface deficient cocrystal synergizes with bimetallic nanoparticles against bacterial infection in wounds. Journal of Colloid and Interface Science. 695. 137805–137805. 3 indexed citations

Yin, Lifang, Yi Zhao, Qiang Gao, et al.. (2025). Regulation of heteroatom positioning in multiple resonance thermally activated delayed fluorescence materials: performance optimization for blue/red emission. Chemical Science. 17(5). 2599–2615. 1 indexed citations

Yang, Lei, Jingjing Li, Pengbo Zhao, et al.. (2025). Notch1 siRNA and AMD3100 Ameliorate Metabolic Dysfunction-Associated Steatotic Liver Disease. Biomedicines. 13(2). 486–486.

Qin, Chao, Xue Wang, Shuo Li, et al.. (2025). Hybrid prodrug nanoassembly for hypoxia-triggered immunogenic chemotherapy and immune modulation. Journal of Controlled Release. 379. 221–235. 3 indexed citations

Li, Shuo, et al.. (2024). Immune cell-derived extracellular vesicles for precision therapy of inflammatory-related diseases. Journal of Controlled Release. 368. 533–547. 16 indexed citations

Wang, Yawen, et al.. (2024). Tenascin C-Guided Nanosystem for Precision Delivery of Obeticholic Acid in Liver Fibrosis Therapy. Pharmaceutics. 17(1). 32–32.

Liu, Lisha, Xiaopeng Han, Xiaofei Xin, et al.. (2024). Bioresponsive nanocomplex integrating cancer-associated fibroblast deactivation and immunogenic chemotherapy for rebuilding immune-excluded tumors. Nanomedicine Nanotechnology Biology and Medicine. 58. 102743–102743. 4 indexed citations

Zhou, Yong, Lei Yang, Di Wu, et al.. (2023). Topical Delivery of ROS-Responsive Methotrexate Prodrug Nanoassemblies by a Dissolvable Microneedle Patch for Psoriasis Therapy. International Journal of Nanomedicine. Volume 18. 899–915. 36 indexed citations

Xia, Yanming, Yanming Xia, Li‐Xin Hu, et al.. (2023). Rational surface modification of zirconium-based metal–organic framework nanomaterials for the adsorption and recovery of coloured drugs and proteins from aqueous solutions. Colloids and Surfaces A Physicochemical and Engineering Aspects. 681. 132845–132845. 7 indexed citations

10.

Zhang, Pan, Chao Qin, Nan Liu, et al.. (2022). The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment. Biomaterials. 284. 121518–121518. 51 indexed citations

11.

Zhang, Kai, Jingjing Li, Xiaofei Xin, et al.. (2021). Dual Targeting of Cancer Cells and MMPs with Self-Assembly Hybrid Nanoparticles for Combination Therapy in Combating Cancer. Pharmaceutics. 13(12). 1990–1990. 15 indexed citations

12.

Xu, Siyuan, Xiaopeng Han, Wei Wang, et al.. (2019). Sustained Release Bilayer Tablet of Ibuprofen and Phenylephrine Hydrochloride: Preparation and Pharmacokinetics in Beagle Dogs. AAPS PharmSciTech. 20(2). 86–86. 5 indexed citations

13.

Teng, Chao, Zhongyue Yuan, Chenshi Lin, et al.. (2019). Desirable PEGylation for improving tumor selectivity of hyaluronic acid-based nanoparticles via low hepatic captured, long circulation times and CD44 receptor-mediated tumor targeting. Nanomedicine Nanotechnology Biology and Medicine. 24. 102105–102105. 21 indexed citations

14.

Lv, Yaqi, Xiangmei Zhao, Lidan Zhu, et al.. (2018). Targeting intracellular MMPs efficiently inhibits tumor metastasis and angiogenesis. Theranostics. 8(10). 2830–2845. 71 indexed citations

15.

Qin, Chao, et al.. (2018). Amorphous Nanosuspensions Aggregated from Paclitaxel–Hemoglobulin Complexes with Enhanced Cytotoxicity. Pharmaceutics. 10(3). 92–92. 7 indexed citations

16.

Jin, Xin, Mengying Li, Lifang Yin, et al.. (2016). Tyroservatide-TPGS-paclitaxel liposomes: Tyroservatide as a targeting ligand for improving breast cancer treatment. Nanomedicine Nanotechnology Biology and Medicine. 13(3). 1105–1115. 20 indexed citations

17.

Zhou, Jianping, et al.. (2015). A toxic organic solvent-free technology for the preparation of PEGylated paclitaxel nanosuspension based on human serum albumin for effective cancer therapy. International Journal of Nanomedicine. 10. 7397–7397. 21 indexed citations

18.

Qin, Chao, Bing He, Wenbing Dai, et al.. (2014). The impact of a chlorotoxin-modified liposome system on receptor MMP-2 and the receptor-associated protein ClC-3. Biomaterials. 35(22). 5908–5920. 43 indexed citations

19.

He, Wei, et al.. (2014). Matrix tablets for sustained release of repaglinide: Preparation, pharmacokinetics and hypoglycemic activity in beagle dogs. International Journal of Pharmaceutics. 478(1). 297–307. 25 indexed citations

20.

Yin, Lifang, et al.. (2010). Preparation and formulation optimization of silymarin sustained-release tablets.. Zhongguo yaoke daxue xuebao. 41(4). 348–352. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact